Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SM (ADAR)
- Development stage
- Unknown
- Lead developer
- SoftMining
- Modality
- Small Molecules
01
Overview
SM (ADAR) is a discovery-stage small molecule therapeutic candidate being developed by SoftMining. The program targets Adenosine Deaminase Acting on RNA (ADAR), an enzyme that converts adenosine to inosine in double-stranded RNA (dsRNA) substrates. In many cancers, ADAR1 is overexpressed and suppresses the innate immune system by editing endogenous dsRNA to prevent it from activating pattern recognition receptors like MDA5. By inhibiting ADAR, the drug aims to trigger a type I interferon response and enhance the tumor's sensitivity to immune checkpoint inhibitors. SoftMining utilizes its proprietary computational drug discovery platform to identify and optimize these inhibitors for potential applications in oncology.
Beyond the preview
Go deeper on SM (ADAR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SM (ADAR).